- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03940963
Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain (REPOSE)
July 24, 2023 updated by: Axogen Corporation
A Multicenter, Prospective, Randomized and Subject Blinded Comparative Study of AxoGuard® Nerve Cap and Neurectomy for the Treatment of Symptomatic Neuroma and Prevention of Recurrent End-Neuroma Pain
Comparing safety, pain, user experience, healthcare economic costs, work productivity, impairment and quality of life outcomes between Axoguard® Nerve Cap and neurectomy in the treatment of symptomatic neuromas in the foot.
Study consists of a 15 subject pilot phase with Axoguard® Nerve Cap implants followed for 3 months and then a comparative study of 86 subjects randomized between the treatment groups followed for 12 months.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
101
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90063
- New Hope Podiatry Group
-
-
Florida
-
Saint Augustine, Florida, United States, 32080
- Anastasia Medical Group
-
-
Georgia
-
Roswell, Georgia, United States, 30076
- EHI Clinical Research
-
-
Illinois
-
O'Fallon, Illinois, United States, 62269
- Gateway Clinical Trials
-
Rockford, Illinois, United States, 61107
- OrthoIllinois
-
Springfield, Illinois, United States, 62704
- Foot and Ankle Center of Illinois
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Texas
-
Austin, Texas, United States, 78746
- Austin Foot and Ankle Specialists
-
Denton, Texas, United States, 76210
- Complete Foot and Ankle Care of North Texas
-
Fort Worth, Texas, United States, 76104
- JPS Health Network
-
-
Utah
-
Saint George, Utah, United States, 84770
- Foot & Ankle Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria (Potential Subjects must):
- Be able and willing to provide documented informed consent prior to the conduct of any study procedures;
- Be an adult male or non-pregnant female ≥ 18 years of age;
- Report baseline pain scores of >65mm on a 100mm Visual Analog Scale (VAS) at screening;
- Have a documented diagnosis of symptomatic neuroma of at least one interdigital nerve in the foot which cannot be repaired to a distal nerve end;
Must have the of the following:
- Pain with at least 3 of the following characteristics: burning, sharp, shooting, electric, parasthesias, numbness, cold intolerance;
- Symptoms in a defined neural anatomic distribution
- History of nerve injury or suspected nerve injury
Must have at least 1:
- Positive response to local anesthetic injection
- US or MRI confirmation of neuroma
- Be candidates indicated for surgery to address a symptomatic neuroma;
- Have sufficient healthy soft tissue available to adequately cover the Axoguard® Nerve Cap;
- In the surgeon's opinion, be likely to achieve complete resection of the symptomatic neuroma and be able to undergo implantation with the Axoguard® Nerve Cap or complete the neurotomy procedure in the control group;
- Be willing and able to comply with all aspects of the treatment and evaluation schedule over a 12-month duration.
Exclusion Criteria (Potential Subjects must not):
- Have undergone surgical treatment of pain from symptomatic neuroma in the target nerve(s)on three or more occasions;
- Have biomechanical pathology and associated pain (such as plantar fasciitis, bursitis, sesamoid bone pain, tendinitis, etc);
- Have a life expectancy of less than 12 months;
- Have a history of or planned radiotherapy in the area of the end-neuroma;
- be contraindicated for soft tissue implants.; this includes but is not limited to any pathology that would limit the blood supply; compromise healing or indicate the presence of a local infection;
- Have a history of chronic ischemic conditions of the extremity;
- Have a diagnosis of type 1 Diabetes Mellitus; or uncontrolled Type 2 Diabetes Mellitus (at the discretion of the investigator);
- Have a history of diabetic neuropathy;
- Be undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular system;
- Be immunosuppressed, immunocompromised or have planned immunosuppressive therapy within 12 months following the study procedure;
- Have a History of congenital neuropathy or compressive neuropathy affecting the target limb;
- Have a history of prior surgical management of more proximal compressive neuropathies or spinal conditions (e.g. spinal stenosis) not related to the symptomatic neuroma that affect the target limb;
- Currently use or likely need to use medication during the study known to impact nerve regeneration or to cause peripheral neuropathy;
- Be pregnant or plan to become pregnant during the duration of the study;
- Be or have been enrolled in another interventional study within 30 days prior to consenting;
- Have a known allergy to anesthetic agents;
- Have a known sensitivity to porcine derived materials; or
- Be, in the opinion of the Investigator, unsuitable for inclusion in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: AxoGuard® Nerve Cap
Porcine derived extracellular matrix (ECM) based Nerve Termination Device Implantation of appropriate diameter of AxoGuard® Nerve Cap at the time of surgery |
Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
|
Active Comparator: Standard Neurectomy
Standard surgical treatment for symptomatic neuroma entailing neuroma excision.
|
Surgical excision of symptomatic neuroma
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visual Analog Scale (VAS) For Pain Score at 3 post-operative months in Pilot Phase Subjects
Time Frame: 3 months
|
The Visual Analog Scale (VAS) For Pain is a patient reported outcomes scale whereby the patient indicates his/her current pain level by making a mark on a continuous horizontal 10 centimeter (100 millimeter) line.
The distance from the 0 millimeter to the patient's mark corresponds to the amount of pain the subject is currently experiencing.
VAS for Pain data are recorded as the number of millimeters from the left of the line to the patients mark across the range of 0-100 millimeters, with 0 millimeter representing no pain and 100 millimeters representing "the worst pain imaginable".
|
3 months
|
Change in Visual Analog Scale (VAS) For Pain Score at 12 post-operative months in Comparative Phase Subjects.
Time Frame: 12 months
|
The Visual Analog Scale (VAS) For Pain is a patient reported outcomes scale whereby the patient indicates his/her current pain level by making a mark on a continuous horizontal 10 centimeter (100 millimeter) line.
The distance from the 0 millimeter to the patient's mark corresponds to the amount of pain the subject is currently experiencing.
VAS for Pain data are recorded as the number of millimeters from the left of the line to the patients mark across the range of 0-100 millimeters, with 0 millimeter representing no pain and 100 millimeters representing "the worst pain imaginable".
|
12 months
|
Safety: Serious Adverse Events (SAEs)
Time Frame: 3 months
|
The primary safety endpoint will compare the nature and incidence of SAEs between treatment groups
|
3 months
|
Safety: Adverse Events (AEs) or Unanticipated Adverse Device Effects (UADEs)
Time Frame: 3 months
|
The primary safety endpoint will compare the nature and incidence of AEs between treatment groups
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Visual Analog Scale (VAS) For Pain score through 12 post-operative months compared to baseline.
Time Frame: 1, 3, 6, 9, and 12 months
|
The Visual Analog Scale (VAS) For Pain is a patient reported outcomes scale whereby the patient indicates his/her current pain level by making a mark on a continuous horizontal 10 centimeter (100 millimeter) line.
The distance from the 0 millimeter to the patient's mark corresponds to the amount of pain the subject is currently experiencing.
VAS for Pain data are recorded as the number of millimeters from the left of the line to the patients mark across the range of 0-100 millimeters, with 0 millimeter representing no pain and 100 millimeters representing "the worst pain imaginable".
|
1, 3, 6, 9, and 12 months
|
2. Change in Patient Reported Outcome Measurement Information System (PROMIS®) - Pain Related Measures through 12 post-operative months compared to baseline.
Time Frame: Time Frame: 1, 3, 6, 9 and 12 months
|
The Patient Reported Outcome Measurement Information System (PROMIS®) - Pain Related Measures is a set of person-centered measures that evaluates and monitors a patient's physical health and pain.
The PROMIS - pain related measures include domains evaluating fatigue, pain intensity, paint interference, sleep Disturbance, and Pain Behavior.
Short forms containing fixed sets of 4-10 items or questions are included for each domain.
All PROMIS scores are presented as T-scores where the T-score is the standardized score with a mean of 50 (range 20-80) and a standard deviation of 10.
Higher scores indicate more of the concept being measures where sometimes the concept is desirable (e.g., physical function) and sometimes this it is undesirable (e.g., fatigue).
PROMIS instruments are scored using item-level calibrations based on response patterns by HealthMeasures Scoring Service (https://www.assessmentcenter.net/ac_scoringservice).
|
Time Frame: 1, 3, 6, 9 and 12 months
|
Change in Foot Health Status Questionnaire (FHSQ) Score at 1,3,6,9, and 12 post-operative months compared to baseline.
Time Frame: Time Frame: 1, 3, 6, 9 and 12 months
|
The Foot Health Status Questionnaire (FHSQ) measures foot health related to quality of life based on responsiveness in overall foot health status in 4 subscale areas (foot function, foot health, footwear and foot pain).
The FHSQ is comprised of 13 questions.
The questionnaire is self-administered.
Subscale ratings are summed and the FHSQ score is reported as 0 (representing poorest state of foot health) to 100 (representing optimal foot health) with higher scores reflecting better foot health and quality of life.
|
Time Frame: 1, 3, 6, 9 and 12 months
|
Changes in quantity, quality and class of pain medication use at 1,3,6,9 and 12 months comparted to baseline.
Time Frame: Time Frame: 1, 3, 6, 9 and 12 months
|
Subjects will maintain a daily pain medication and concomitant medication diary which logs the quantity, quality, and class of pain medication administered and taken at 1,3,6,9 and 12 post-operative months.
|
Time Frame: 1, 3, 6, 9 and 12 months
|
SAEs, AEs, and/or UADEs
Time Frame: 6, 9, and 12 months
|
The secondary safety endpoint will compare the nature and incidence of SAEs, AEs, and UADEs between treatment groups
|
6, 9, and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2018
Primary Completion (Actual)
July 17, 2023
Study Completion (Actual)
July 17, 2023
Study Registration Dates
First Submitted
May 6, 2019
First Submitted That Met QC Criteria
May 6, 2019
First Posted (Actual)
May 7, 2019
Study Record Updates
Last Update Posted (Actual)
July 25, 2023
Last Update Submitted That Met QC Criteria
July 24, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAP-CP-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic Neuroma
-
Axogen CorporationRecruitingAmputation | Symptomatic Neuroma | Chronic Nerve PainUnited States
-
Northwestern UniversityAmerican Society for Surgery of the HandEnrolling by invitationNeuroma Amputation | Neuroma | Neuroma of Upper Limb | Neuroma of Lower LimbUnited States
-
Centrexion TherapeuticsCompletedPainful Intermetatarsal Neuroma (Morton's Neuroma)United States
-
Queen Margaret UniversityUnknown
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingAmputation | Amputation NeuromaUnited States
-
Rigshospitalet, DenmarkHvidovre University Hospital; Bispebjerg Hospital; The Danish Rheumatism Association and other collaboratorsRecruitingMorton Neuroma | Intermetatarsal Neuroma | Intermetatarsal BursitisDenmark
-
Oregon Health and Science UniversityCompletedNeuroma AmputationUnited States
-
Peking University People's HospitalRecruitingAmputation NeuromaChina
-
Gaziler Physical Medicine and Rehabilitation Education...CompletedNeuroma AmputationTurkey
-
University of MichiganUniversity of California, San FranciscoWithdrawnAmputation | Prosthesis User | Amputation NeuromaUnited States
Clinical Trials on AxoGuard® Nerve Cap
-
Axogen CorporationRecruitingAmputation | Symptomatic Neuroma | Chronic Nerve PainUnited States
-
University of Mississippi Medical CenterUnknownSpinal Accessory Nerve Injury | Cervical LymphadenopathyUnited States
-
Axogen CorporationRecruitingRecurrent Cubital Tunnel Syndrome | Recalcitrant Cubital Tunnel SyndromeUnited States
-
Carlos TorneroCompleted
-
LivaNovaCompletedHeart Failure With Reduced Ejection FractionFrance, Serbia, Norway, Belgium
-
Aalborg University HospitalAalborg UniversityRecruitingLactobacillus Infection | Cystitis RecurrentDenmark
-
Smiths Medical, ASD, Inc.UnknownPeripheral Nerve Block ProcedureUnited Kingdom
-
Stanford UniversitySPR Therapeutics, Inc.WithdrawnPostoperative Pain | Knee Injuries | Surgery | Total Knee Arthroplasty | Knee Pain Chronic | Chronic Postoperative Pain | Injury; Nerve, Peripheral, Multiple | Chronic Post-Procedural PainUnited States
-
University Hospital, GhentCompleted
-
Centre Hospitalier Universitaire de NīmesUniversity Hospital, LimogesRecruitingColorectal Cancer | Adenoma | Intestinal PolypsFrance